Biospace med Expands U.S. Market Penetration with ‘EOS’, which Cuts Radiation up to 90% vs. Conventional X-Rays

CAMBRIDGE, Mass. & PARIS–(BUSINESS WIRE)–Biospace med announced today that it continues to penetrate the U.S. market with its FDA-cleared ‘EOS’ x-ray imager—the world’s first ultra-low-dose x-ray technology—recently adding new customers in the Midwest and Southeast regions of the United States. In addition, Professor Georges Charpak, inventor of the EOS technology, has received the ‘Centenary Medal’ from the French Radiological Society (SFR), the esteemed organization’s highest honor.

EOS can capture head-to-toe images of patients in a standing, weight-bearing position with a dramatic reduction in radiation dose—up to 10 times less than a conventional x-ray and up to 1000 times less than a CT (Computed Tomography) scan. Additionally, EOS images are designed to provide sharp detail and empower physicians to better diagnose and plan an effective course of treatment.

“We are very pleased to announce additional installations of our ultra-low-dose EOS x-ray imager in new markets across the United States,” said Marie Meynadier, Ph.D., chief executive officer of Biospace med. “Now that we have a beachhead in two new regions of the United States, we look forward to meeting the numerous healthcare institutions in these new markets that are still imaging patients with a conventional digital x-ray, as they are in the front rank of candidates to adopt EOS.